Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1947760 | Biochimica et Biophysica Acta (BBA) - General Subjects | 2012 | 4 Pages |
BackgroundMitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) is the most common type of mitochondrial disease and is characterized by stroke-like episodes (SEs), myopathy, lactic acidosis, diabetes mellitus, hearing-loss and cardiomyopathy. The causal hypotheses for SEs in MELAS presented to date are angiopathy, cytopathy and neuronal hyperexcitability. L-arginine (Arg) has been applied for the therapy in MELAS patients.Scope of reviewWe will introduce novel in vivo functional brain imaging techniques such as MRI and PET, and discuss the pathogenesis of SEs in MELAS patients. We will further describe here our clinical experience with L-arg therapy and discuss the dual pharmaceutical effects of this drug on MELAS.Major conclusionsAdministration of L-arg to MELAS patients has been successful in reducing neurological symptoms due to acute strokes and preventing recurrences of SEs in the chronic phase. L-Arg has dual pharmaceutical effects on both angiopathy and cytopathy in MELAS.General significanceIn vivo functional brain imaging promotes a better understanding of the pathogenesis and potential therapies for MELAS patients. This article is part of a Special Issue entitled Biochemistry of Mitochondria, Life and Intervention 2010.
► Several novel in vivo functional brain imaging techniques were described. ► Such imaging techniques evaluated various conditions in MELAS patients. ► l-Arg has dual pharmaceutical effects on both angiopathy and cytopathy in MELAS.